Oliver Ottmann

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi request reprint Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Barbara Wassmann
    Departments of Hematology Oncology of University Hospitals Frankfurt, Hannover, Dresden, Munster, Ulm, Heidelberg, Munich, Germany
    Blood 106:458-63. 2005
  2. ncbi request reprint FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment
    Dali Cai
    Universitätsklinikum Marburg und Giessen, Standort Marburg, Klinik für Hämatologie, Onkologie, und Immunologie, Marburg, Germany
    Blood 107:2094-7. 2006
  3. pmc Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    Afsar Ali Mian
    Department of Hematology, Goethe University, Frankfurt, Germany
    BMC Cancer 12:411. 2012
  4. pmc Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression
    Gianni Capalbo
    Department of Hematology Oncology and Infectious Diseases, J W Goethe University Hospital, Theodor Stern Kai 7, Frankfurt Main, Germany
    Retrovirology 7:26. 2010
  5. pmc The DAC system and associations with acute leukemias and myelodysplastic syndromes
    Gesine Bug
    Medizinische Klinik II, Abteilung für Hämatologie und Onkologie der, Goethe Universitat, Theodor Stern Kai 7, 60590, Frankfurt, Germany
    Invest New Drugs 28:S36-49. 2010
  6. ncbi request reprint Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts
    Oliver G Ottmann
    Medizinische Klinik III, Abteilung für Hämatologie und Onkologie, Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590, Frankfurt, Germany
    Best Pract Res Clin Haematol 15:757-69. 2002
  7. ncbi request reprint Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms
    Patrick Bruck
    Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt a M, Germany
    Leuk Res 28:1153-7. 2004
  8. ncbi request reprint Growth factors in the treatment of acute lymphoblastic leukemia
    O G Ottmann
    Department of Hematology and Oncology, Medizinische Klinik III des Johann Wolfgang Goethe Universität, Frankfurt, Germany
    Leuk Res 22:1171-8. 1998
  9. doi request reprint First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults
    Oliver G Ottmann
    Medizinische Klinik II, Department of Hematology and Oncology, Goethe University, Frankfurt, Germany
    Curr Opin Oncol 21:S43-6. 2009
  10. ncbi request reprint A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
    Oliver G Ottmann
    Medizinische Klinik III Abteilung Haematologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Blood 100:1965-71. 2002

Detail Information

Publications64

  1. ncbi request reprint Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Barbara Wassmann
    Departments of Hematology Oncology of University Hospitals Frankfurt, Hannover, Dresden, Munster, Ulm, Heidelberg, Munich, Germany
    Blood 106:458-63. 2005
    ..Continued detection of bcr-abl transcripts after 2 to 3 months on imatinib identifies patients who will ultimately experience relapse and in whom additional or alternative antileukemic treatment should be initiated...
  2. ncbi request reprint FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment
    Dali Cai
    Universitätsklinikum Marburg und Giessen, Standort Marburg, Klinik für Hämatologie, Onkologie, und Immunologie, Marburg, Germany
    Blood 107:2094-7. 2006
    ..This warrants the application of HDI-based therapies in poor-risk Ph+ ALL, and the use of Akt/mTor inhibitors to overcome HDI resistance in AML...
  3. pmc Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    Afsar Ali Mian
    Department of Hematology, Goethe University, Frankfurt, Germany
    BMC Cancer 12:411. 2012
    ..Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia...
  4. pmc Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression
    Gianni Capalbo
    Department of Hematology Oncology and Infectious Diseases, J W Goethe University Hospital, Theodor Stern Kai 7, Frankfurt Main, Germany
    Retrovirology 7:26. 2010
    ..To examine whether GliPR plays a role as HIV dependency factor (HDF), we tested the effect of GliPR suppression by siRNA on HIV-1 replication...
  5. pmc The DAC system and associations with acute leukemias and myelodysplastic syndromes
    Gesine Bug
    Medizinische Klinik II, Abteilung für Hämatologie und Onkologie der, Goethe Universitat, Theodor Stern Kai 7, 60590, Frankfurt, Germany
    Invest New Drugs 28:S36-49. 2010
    ....
  6. ncbi request reprint Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts
    Oliver G Ottmann
    Medizinische Klinik III, Abteilung für Hämatologie und Onkologie, Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590, Frankfurt, Germany
    Best Pract Res Clin Haematol 15:757-69. 2002
    ..Better understanding of targeted therapies, including strategies based on recruitment of host immune functions, as well as the prudent use of active chemotherapy agents, may eventually improve the outlook for patients with Ph(+) ALL...
  7. ncbi request reprint Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms
    Patrick Bruck
    Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt a M, Germany
    Leuk Res 28:1153-7. 2004
    ..SNPs of PDGFR genes do not appear to play a role in patient's susceptibility to clinically severe edema formation during treatment with STI571...
  8. ncbi request reprint Growth factors in the treatment of acute lymphoblastic leukemia
    O G Ottmann
    Department of Hematology and Oncology, Medizinische Klinik III des Johann Wolfgang Goethe Universität, Frankfurt, Germany
    Leuk Res 22:1171-8. 1998
    ..As the remaining open questions are resolved, clinical benefits may be achieved consistently and with a favorable cost benefit ratio...
  9. doi request reprint First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults
    Oliver G Ottmann
    Medizinische Klinik II, Department of Hematology and Oncology, Goethe University, Frankfurt, Germany
    Curr Opin Oncol 21:S43-6. 2009
    ..Following SCT, the pre-emptive use of imatinib appears to reduce the relapse rate. Novel immunotherapeutic interventions and combinations of TKI are also being explored...
  10. ncbi request reprint A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
    Oliver G Ottmann
    Medizinische Klinik III Abteilung Haematologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Blood 100:1965-71. 2002
    ..Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib...
  11. ncbi request reprint Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
    Oliver Ottmann
    Medizinische Klinik II, Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Blood 110:2309-15. 2007
    ..Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015...
  12. ncbi request reprint Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia
    Oliver G Ottmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Semin Hematol 44:183-92. 2007
    ..Selection of those patients likely to benefit from growth factors in a specific clinical setting is a worthwhile endeavour...
  13. ncbi request reprint Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
    Oliver G Ottmann
    Department of Hematology, University Hospital of Frankfurt, Germany
    Cancer 109:2068-76. 2007
    ..Imatinib in combination with intensive chemotherapy has yielded promising results as front-line therapy, but its value as monotherapy in newly diagnosed Ph+ALL is not known...
  14. ncbi request reprint [Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec)]
    Oliver G Ottmann
    Abteilung Hämatologie Onkologie, Medizinische Klinik III der Johann Wolfgang Goethe Universität Frankfurt Main
    Med Klin (Munich) 97:16-21. 2002
    ..The recent development of the selective abl-tyrosine kinase inhibitor Glivec (formerly STI571) opens the opportunity of blocking the signal transduction pathways critically involved in bcr-abl induced leukemogenesis...
  15. doi request reprint Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Ann Hematol 91:1221-33. 2012
    ..Expression of the MEBE genes is regulated by FLI1 and c-MYC, which are potential upstream targets of the MEBE signature...
  16. doi request reprint Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Oncol 29:2499-506. 2011
    ..To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS)...
  17. ncbi request reprint Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis
    Elena Puccetti
    Med Klinik III Abtl Hämatologie, Johann Wolfgang Goethe Universitat, D 60590 Frankfurt, Germany
    Oncogene 22:6900-8. 2003
    ..In summary, these data suggest a crucial role of factors able to upregulate PML for As2O2-induced cell death...
  18. doi request reprint Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
    Katharina Wagner
    Department of Hematology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Oncol 28:2356-64. 2010
    ....
  19. pmc IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Haematologica 95:1668-74. 2010
    ..However, little is known about the incidence and prognostic impact of IDH1 and IDH2 mutations in myelodysplastic syndromes...
  20. ncbi request reprint Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Barbara Wassmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Blood 108:1469-77. 2006
    ..Both schedules of imatinib have acceptable toxicity and facilitate SCT in CR1 in the majority of patients, but concurrent administration of imatinib and chemotherapy has greater antileukemic efficacy...
  21. ncbi request reprint Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Heike Pfeifer
    Center for Internal Medicine, Department of Hematology Oncology, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Blood 110:727-34. 2007
    ..This provides a rationale for the frontline use of kinase inhibitors active against these BCR-ABL mutants...
  22. doi request reprint Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Blood 119:3578-84. 2012
    ..83; 95% confidence interval, 1.31-6.12; P = .008). These results show a negative prognostic impact of SRSF2 mutations in MDS. SRSF2 mutations may become useful for clinical risk stratification and treatment decisions in the future...
  23. doi request reprint Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement
    Joerg Baeumler
    Department of Hematology, JW Goethe University, Frankfurt am Main, Germany
    Cancer Genet Cytogenet 185:37-42. 2008
    ..Furthermore, the cells displayed a del(9)(p21.1 approximately p23), typically associated with loss of CDKN2A and CDKN2B. The ALL-VG cell line may serve as a tool for the study of ETV6/ABL1...
  24. pmc The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
    Patricia Mambou Gwanmesia
    Med, Klinik II Abt, Hämatologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    BMC Cancer 9:53. 2009
    ..Here, we investigated the biological effect of the new specific dual Src/Abl kinase inhibitor AZD0530 on Ph+ leukaemic cells...
  25. ncbi request reprint Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
    Blood 99:1860-2. 2002
    ..Glu255Lys is within the motif important for forming the pocket of the ATP-binding site in ABL and it is highly conserved across species. In conclusion, Ph(+) ALL samples resistant to STI571 have a unique mutation Glu255Lys of BCR-ABL...
  26. ncbi request reprint Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study
    Wolf K Hofmann
    Division of Haematology and Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Lancet 359:481-6. 2002
    ..However, resistance to this drug develops within a few months in most patients. We aimed to predict resistance to STI571...
  27. ncbi request reprint Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
    Gesine Bug
    Medizinische Klinik II, Abt Hämatologie Onkologie, Klinikum der Johann Wolfgang Goethe Universitat Frankfurt, Theodor Stern Kai 7, Frankfurt, Germany
    Haematologica 92:542-5. 2007
    ..Our data suggest a differential effect of VPA on the small population of AML progenitor cells and the bulk of aberrantly differentiated blasts in the majority of AML samples tested...
  28. ncbi request reprint The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities
    Oliver G Ottmann
    Medizinische Klinik III, Department of Hematology and Oncology, Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Hematol J 3:2-6. 2002
  29. ncbi request reprint Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis
    Gesine Bug
    Department of Internal Medicine II, University Hospital, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Transfusion 47:1843-50. 2007
    ..Although the efficacy of leukapheresis in terms of prompt cytoreduction is generally accepted, published data regarding the clinical value of immediate therapeutic leukapheresis are limited and conflicting...
  30. ncbi request reprint Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
    Wolf Karsten Hofmann
    Department of Hematology, University Hospital, Theodor Stern Kai 7, 60596, Frankfurt Main, Germany
    Blood 102:659-61. 2003
    ..The findings suggest that the mutation exists in a very small subpopulation of leukemic cells at the beginning of STI571 therapy...
  31. ncbi request reprint Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
    Dieter Hoelzer
    Department of Hematology Oncology, University of Frankfurt, Frankfurt, Germany
    Semin Hematol 39:32-7. 2002
    ....
  32. ncbi request reprint Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
    Urban J Scheuring
    Medizinische Klinik III, Abteilung für Hämatologie und Onkologie of the Johann Wolfgang Goethe Universität, Frankfurt, Germany
    Blood 101:85-90. 2003
    ..The data show that Bcr-Abl levels in PB and BM after 2 weeks of imatinib treatment and in BM after 4 weeks have predictive relevance and may guide the application of additional therapies...
  33. pmc Expression of interleukin-18 receptor in fibroblast-like synoviocytes
    Burkhard Möller
    Rheumazentrum Rhein Main, Marienburgstrasse 2, D 60528 Frankfurt, Germany
    Arthritis Res 4:139-44. 2002
    ..We conclude that the presence of macrophages or IL-18R+ T cells that can respond directly to IL-18 is essential for the proinflammatory effects of IL-18 in synovitis in RA...
  34. ncbi request reprint Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate
    Heike Pfeifer
    Department of Hematology, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Clin Cancer Res 9:4674-81. 2003
    ..It was the aim of this analysis to determine the incidence of, and risk factors associated with, meningeal leukemia during imatinib monotherapy...
  35. ncbi request reprint Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors
    Burkhard Möller
    Medizinische Klinik III, Klinikum der Johann Wolfgang, Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt M, Germany
    Rheumatol Int 22:60-7. 2002
    ..Here we investigated whether a folate excess impairs monocyte differentiation, a putative anti-inflammatory action of low-dose MTX...
  36. ncbi request reprint Regulation of human IL-18 gene expression: interaction of PU.1 with GC-box binding protein is involved in human IL-18 expression in myeloid cells
    Noriko Koyama
    Department of Hematology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Eur J Immunol 34:817-26. 2004
    ....
  37. ncbi request reprint Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia
    Wolf K Hofmann
    Department of Hematology and Oncology, University Hospital, Frankfurt Main, Germany
    Leuk Lymphoma 45:655-60. 2004
    ..This may result in the proliferation of Ph + leukemic cells even in the presence of STI571...
  38. doi request reprint Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome
    Saskia Gueller
    Department of Hematology and Oncology, University Hospital, Frankfurt Main, Germany
    Exp Hematol 38:718-32, 732.e1-6. 2010
    ....
  39. ncbi request reprint Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia
    Annette Romanski
    Med Klinik III Abtl Hämatologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Haematologica 89:419-26. 2004
    ..HDAC inhibitors interfere with differentiation, proliferation and apoptosis in tumor cells. Here, we investigated the activity of a new hydroxamic acid derivative, LAQ824, on lymphoblastic cells...
  40. ncbi request reprint Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation
    Martina Komor
    Department of Hematology, Oncology and Transfusion Medicine, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Stem Cells 23:1154-69. 2005
    ..The expression of selected genes was confirmed by real-time polymerase chain reaction. Our data encompass the first extensive transcriptional profile of human hematopoiesis during in vitro lineage-specific differentiation...
  41. doi request reprint Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study
    Friederike Braulke
    Department of Hematology and Oncology, University of Goettingen, Germany
    Leuk Res 37:900-6. 2013
    ..We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. ..
  42. doi request reprint Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia
    Frederik Damm
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    J Clin Oncol 28:578-85. 2010
    ..We assessed the prognostic impact of a known single nucleotide polymorphism (SNP) located in the mutational hotspot of WT1 in patients with cytogenetically normal acute myeloid leukemia (CN-AML) in the context of other prognostic markers...
  43. ncbi request reprint Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia
    Annette Romanski
    Center for Internal Medicine, Department of Hematology Oncology, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Exp Hematol 33:344-52. 2005
    ..Acute lymphoblastic leukemias (ALL) often display a high degree of resistance, the mechanisms of which have not been elucidated...
  44. ncbi request reprint Comparison of TaqMan real-time PCR and p24 Elisa for quantification of in vitro HIV-1 replication
    Stefan A Klein
    Medizinische Klinik III der Johann Wolfgang Goethe Universität, Theodor Stern Kai 7, D 60590, Frankfurt, Germany
    J Virol Methods 107:169-75. 2003
    ..It is suggested, therefore, that this technique be an alternative method to monitor HIV-1 replication in vitro...
  45. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    Philipp Le Coutre
    Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    Blood 111:1834-9. 2008
    ..In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228...
  46. doi request reprint Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
    Paul La Rosée
    III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3 68167 Mannheim, Germany
    Haematologica 93:765-9. 2008
    ..Monitoring the actual BCR-ABL inhibition in nilotinib treated patients using pCRKL as a surrogate is a means to establish effective dosing and to characterize resistance mechanisms against nilotinib...
  47. ncbi request reprint Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    Charles L Sawyers
    Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Blood 99:3530-9. 2002
    ..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
  48. ncbi request reprint Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
    Moshe Talpaz
    M D Anderson Cancer Center, Houston, Texas, USA
    Blood 99:1928-37. 2002
    ..Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity...
  49. ncbi request reprint Coordination of cell growth in cocultures by a genetic proliferation control system
    Katharina Schroeder
    Department of Gene Regulation and Differentiation, German Research Center for Biotechnology, D 38124 Braunschweig, Germany
    Biotechnol Bioeng 78:346-52. 2002
    ..The results demonstrate the applicability of genetic proliferation control to coordinate growth of different cell types in cocultures...
  50. ncbi request reprint The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate
    Junya Kuroda
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Blood 102:2229-35. 2003
    ..These findings indicate that ZOL is a potent antileukemic agent that augments synergistically the anti-Ph+ leukemia activity of imatinib mesylate...
  51. ncbi request reprint A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
    Walter Fiedler
    Department of Oncology Hematology, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Blood 102:2763-7. 2003
    ....
  52. ncbi request reprint Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib
    Barbara Wassmann
    Department of Hematology Oncology, University Hospital Frankfurt, Germany
    Blood 103:1495-8. 2004
    ..Conversely, patients with clinically or cytogenetically defined poor-risk features are candidates for trials of upfront imatinib in combination with other agents...
  53. ncbi request reprint Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Hematol 79:37-43. 2004
    ..Furthermore, one day of ZOL pretreatment augmented the sensitivity of imatinib and Ara-C. Therefore, concurrent or sequential administration of ZOL with imatinib, HU, Ara-C, or DNR may increase the efficacy of leukemia treatment...
  54. ncbi request reprint Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Br J Haematol 130:558-60. 2005
    ..These findings suggest that the combination of ZOL and imatinib accelerate the eradication of Ph+ clone, resulting in better prognosis of Ph+ leukaemia patients who have not yet acquired mutations...
  55. ncbi request reprint Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
    Gesine Bug
    Department of Internal Medicine II, University Hospital, JW Goethe University Frankfurt, Germany
    Cancer 104:2717-25. 2005
    ..Clinical responses to VPA were recently observed in patients with myelodysplastic syndrome (MDS). Herein, the authors have described results of a clinical trial with VPA plus ATRA in 26 patients with poor-risk AML...
  56. ncbi request reprint Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis
    Stefan Fruehauf
    Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer 109:1543-9. 2007
    ..Imatinib has demonstrated synergistic effects in vitro with mitoxantrone, etoposide, and cytarabine...
  57. ncbi request reprint Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells
    Christian Wichmann
    Institute for Biomedical Research, Georg Speyer Haus, Paul Ehrlich Strasse 42 44, 60596 Frankfurt M, Germany
    Cancer Res 67:2280-9. 2007
    ..Our results indicate that selective interference with the oligomerization domain of ETO could provide a promising strategy to inhibit the oncogenic properties of the leukemia-associated fusion protein RUNX1/ETO...
  58. ncbi request reprint Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation
    Steffen Koschmieder
    Department of Internal Medicine Hematology and Oncology, University Hospital of Munster, Germany
    Int J Oncol 30:349-55. 2007
    ..In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity...
  59. pmc Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
    Junya Kuroda
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
    Proc Natl Acad Sci U S A 103:14907-12. 2006
    ..These results demonstrate that Bim and Bad account for most, perhaps all, imatinib-induced killing of Bcr/Abl+ leukemic cells and suggest previously undescribed drug combination strategies for cancer therapy...
  60. ncbi request reprint Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    N Engl J Med 354:2542-51. 2006
    ..Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50...
  61. ncbi request reprint p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid
    Junya Kuroda
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Sci 95:186-92. 2004
    ..ZOL also affected the coordinate expression patterns of several cell cycle regulators during the execution of anti-tumor activity...
  62. ncbi request reprint Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Urban J Scheuring
    Haematologica 88:1074-6. 2003
  63. ncbi request reprint A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
    Walter Fiedler
    Department of Oncology Hematology, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Blood 105:986-93. 2005
    ..In summary, monotherapy with SU11248 induced partial remissions of short duration in acute myeloid leukemia (AML) patients. Further evaluation of this compound, for example in combination with chemotherapy, is warranted...
  64. ncbi request reprint An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR
    Martin C Muller
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Haematologica 92:970-3. 2007
    ..5 mL samples tested positive. For higher dilutions, a PB volume of 5 or 10 ml was required to improve sensitivity. The study showed the feasibility of RQ-PCR standardization independent of the PCR machine used...